Science1 month ago
Entrada Therapeutics Unveils Promising DMD and DM1 Data Plans for 2026
Entrada Therapeutics (NASDAQ: TRDA) recently presented its strategic vision for 2026 at the Guggenheim 2026 Emerging Outlook Biotech Summit, highlighting a series of anticipated clinical data...